MORPHOSYS AG O.N. | 82.70 / +0.85% |
Date/Time | 03/05 / 15:11 |
Chg. / Chg.(%) | 0.70 / +0.85% |
Bid | - |
Ask | - |
Open | 81.02 |
Previous Close | 82.00 |
High | 82.70 |
Low | 81.02 |
Volume [EUR] | 3,225.30 |
Volume [Units] | 39 |
Price fixings | 2 |
ISIN | DE0006632003 |
Security | MOR |
Exchange | Hannover |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 81.680 | ![]() |
|
Xetra | 81.60 | ![]() |
125,971 |
Turquoise | 81.28 | ![]() |
28,873 |
Cboe Europe .. | 81.60 | ![]() |
25,487 |
TradeGate | 82.200 | ![]() |
14,639 |
London Inter.. | 81.80 | ![]() |
9,898 |
Stuttgart | 81.740 | ![]() |
857 |
Frankfurt | 81.6800 | ![]() |
677 |
gettex | 81.740 | ![]() |
515 |
Cboe Europe .. | 82.95 | ![]() |
110 |
Cboe Europe .. | 82.90 | ![]() |
106 |
München | 81.68 | ![]() |
72 |
Düsseldorf | 81.52 | ![]() |
66 |
Hannover | 82.70 | ![]() |
39 |
Berlin | 82.00 | ![]() |
25 |
Hamburg | 82.62 | ![]() |
20 |
Vienna Globa.. | 81.78 | ![]() |
0 |
Nasdaq Other.. | 113.1500 | 100 | |
EUREX | Options |
News
- I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Multiple Myeloma in Mainland China
04/27/2020 / 22:01 - GlobeNewswire - MOR106 clinical development in atopic dermatitis stopped for futility
10/28/2019 / 21:45 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:02 - GlobeNewswire - Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis patients
04/23/2019 / 22:01 - GlobeNewswire - Genmab Announces that the Patent Infringement Lawsuit Relating to DARZALEX® is Over
01/31/2019 / 13:36 - GlobeNewswire